Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-fluorodeprenyl (specifically its bis-deuterated version, 18F-fluorodeprenyl-D2 or [18F]F-DED, also known as LNTH-2511) is an investigational fluorine-18-labeled positron emission tomography (PET) radioligand designed to target monoamine oxidase B (MAO-B). MAO-B is an enzyme primarily located on the outer mitochondrial membranes of glial cells and is significantly upregulated in reactive astrocytes during neuroinflammation. By binding selectively to MAO-B, 18F-fluorodeprenyl serves as a diagnostic imaging agent to visualize and quantify reactive astrogliosis in vivo. It is being evaluated as a biomarker for disease activity and progression in neurodegenerative and neuroinflammatory conditions, including Alzheimer's disease, multiple system atrophy (MSA), multiple sclerosis (MS), and autoimmune encephalitis (such as GAD65-antibody and LGI1-antibody autoimmune encephalitis). Originally developed by researchers at the Karolinska Institutet in collaboration with Bayer, the asset was subsequently developed by Life Molecular Imaging, which was acquired by Lantheus in 2025.
| Indication | Highest phase | Status |
|---|---|---|
| Alzheimer's disease (AD) | In development | Active |
| atypical parkinsonian syndromes | Preclinical | Active |
| autoimmune encephalitis | Preclinical | Active |
| dysautonomia | Preclinical | Active |
| multiple sclerosis (MS) | Preclinical | Active |
| multiple system atrophy (MSA) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Patent families, expiry dates and exclusivities are in the full profile.
Lead indication: autoimmune encephalitis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18F-fluorodeprenyl.
Work on 18F-fluorodeprenyl? Claim this page to correct or add information. Claim this page